



Updated Monthly

August 12, 2026

Prepared for:



THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:



Questions?

Liz Powell, Esq., MPH
lpowell@G2Gconsulting.com
www.G2Gconsulting.com

  @G2Gconsulting





TABLE OF CONTENTS

New Opportunities

Artificial Intelligence & Machine Learning	2
Bioengineering	4
Biomedical Research.....	4
Biotechnology and Biomanufacturing.....	5
Cancer	6
Clinical Trials	7
Cognitive and Brain Health.....	8
Diagnostics	8
Down Syndrome	9
Endocrine & Metabolic Disease	9
Environmental Remediation	9
Global Health.....	9
Immunology & Infectious Disease	10
Maternal and Pediatric Health	11
Medical Countermeasures.....	11
Medical Manufacturing	12
Medical Rehabilitation	13
NIH Common Fund.....	13
Nutrition and Obesity Research.....	14
Patient-Centered Research	14
Reconstructive Transplant	14
Small Business Development	15

GBG Report

Updated Monthly

August 12, 2026

<https://www.g2gconsulting.com/gbg-reporting-service/>

Substance Use Disorder	15
Therapeutics.....	15
Women's Health.....	16

Recurring Opportunities

Advanced Research Projects Agency for Health.....	17
Air Force	18
Army.....	19
BARDA	21
DARPA	21
Defense Threat Reduction Agency	22
Department of Energy	23
National Science Foundation	23
Navy	24
Office of the Undersecretary of Defense	24
Patient-Centered Outcomes Research Institute	25

GBG Acronyms	27
--------------------	----



August 20, 2026 – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 12-12:30pm EST (FREE to all) and 12:30-1:00pm (premium service private consultation for G2G and GBG clients). If you’re an affiliate of Biocom, BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Life Sciences Association, Georgia Life Sciences, IowaBio, MichBio, NCBiotech, Ohio Life Sciences, South Dakota Biotech, VaBio, or BioWV – your membership gets you access to the [private consultation meeting](#).

Women’s Health Advocates is planning two Hill Days in September: [Perimenopause & Menopause](#) on September 22, and [Breast Cancer Early Detection Coalition](#) on September 23. Click the links to register!

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARTIFICIAL INTELLIGENCE & MACHINE LEARNING (5)		
1.	Multiscale Reasoning For Human Physiology RFI (DoD/DARPA) DARPA-SN-26-100	This RFI seeks to identify existing capabilities, foundational datasets, and critical scientific gaps in connecting biological and physiological processes across molecular, cellular, tissue, organ, whole-body, and clinical scales. DARPA is seeking information on technologies, models, and datasets relevant to multiscale reasoning in human physiology. The list includes, but is not limited to: Multiscale Computational Models; Foundation Models for Multi-scale Biology and Medicine; Multi-scale Human Physiology Data Resources; Prediction and Intervention Across Scales of Biology and Medicine; and Military and Operational Medicine Applications Leveraging Multi-Scale Modeling Solutions. https://sam.gov/opp/75a6c5433f00498e8b8e6a6fe6892606/view	N/A	Response: 8/20/26
2.	Unlocking Dataset Value for AI-Enabled Scientific Discovery (AI Datasets) (NSF) NSF 26-512	The program seeks to 1) apply AI-based capabilities to feature extraction and metadata generation, and the integration of multiple datasets. 2) Develop robust data pipelines necessary for automated analysis of existing datasets and similar use-cases by AI tools and systems. 3) Augment and/or harmonize existing datasets to better enable use by AI data pipelines and automated analysis. https://www.nsf.gov/funding/opportunities/ai-datasets-unlocking-dataset-value-ai-enabled-scientific-discovery/nsf26-512/solicitation	Up to \$5 million, for up to 3 years Dependent upon award mechanism and available funds	Proposal: 11/4/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARTIFICIAL INTELLIGENCE & MACHINE LEARNING		
3.	Forecast: Bridge2AI Network for AI Health Science (NIH Common Fund) RFA-RM-28-010	Stage 1 of the Bridge2AI program produced unique, large-scale, valuable, and open resource, AI-ready datasets and best practices that the scientific community can adopt. The second stage of the program will foster advances on two fronts: 1) Leverage the AI-ready datasets from Stage 1 to yield products that can address biomedical and behavioral research grand challenges, accelerate the discovery of new biological theories and rules, and advance understanding of biological and behavioral mechanisms of health and disease; 2) Create networks of multidisciplinary researchers to advance the science of AI science by developing necessary metrics and a framework to for trustworthy, reproducible and explainable AI-enabled biomedical and behavioral research. https://www.grants.gov/search-results-detail/363107	Up to \$7 million	Estimated post date: 1/1/27 Estimated proposal date: 3/1/27
4.	AI-Enabled Consumer Engagement to Advance Family Planning (Gates Foundation)	This RFP seeks to answer a core question for the family planning field: can AI-enabled direct-to-consumer engagement improve contraceptive uptake, continuation, and informed method choice at scale - and, if so, which approach works best? This challenge is designed to generate practical evidence on what high-quality, AI-assisted family planning engagement looks like in the AI era. We are interested in understanding which AI-enabled tools are most effective to engage users and improve contraception uptake and continuation. https://gcgh.grandchallenges.org/challenge/ai-enabled-consumer-engagement-advance-family-planning	Up to \$500,000, for up to 1 year	Proposal: 8/25/26
5.	Artificial intelligence in cell culture media and process development (Merck)	In this category, we invite proposals for robust, host-agnostic, and easy to parameterize models, that enable us to more quickly develop fit-for-purpose solutions for the optimization of bioprocesses for a broad base of host organisms. In order to predict optimized media feeds for bioprocessing, we aim to use mechanistic and/or hybrid modeling to better understand the nutrient requirements of mammalian cell lines. Proposals should include a non-confidential description of your model and key parameters relevant for optimizing cell culture media; and the proposed data strategy for continuous improvement ensuring the model's ability to adapt to a range of mammalian host organisms. https://www.emdgroup.com/en/research/open-innovation/research-grants.html	Up to €150,000 per year, for up to 3 years	Application: 8/31/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOENGINEERING (1)		
6.	Protein ENGINEERING (PENG) (DoD/DARPA) DARPA-PS-26-129	The PENG program fundamentally focuses on the direct, transient engineering of endogenous biology. Proposed research must therefore utilize technology to physically edit existing proteins in their native cellular environments, not isolated in vitro protein preparations. Proposed technologies must be adaptable to diverse protein types and edit locations, and performers must demonstrate a clear, credible path to scale their platform from single-cell models into higher-order tissue complexity, including a defined validation strategy for confirming edits in these more complex models. https://sam.gov/workspace/contract/opp/be313c6423e841ae9572a0878b3d9bbb/view	Dependent upon proposal and available funds, for 42 months	Abstract: 8/24/26 Proposal: 10/19/26
		BIOMEDICAL RESEARCH (3)		
7.	Fiscal Year 2026 Multi-Topic Request for Project Proposals (MTEC) MTEC-26-04-MultiTopic	This RPP solicits a broad range of medical prototype technological and knowledge solutions related to the 15 Focus Areas of Interest, including four areas addressing pain treatment. Areas include: Prophylactic Solutions to Prevent Battlefield and Complex Traumatic Wound Infections in Austere or Contested Environments; Pathogen Agnostic Countermeasures for the Treatment of Sepsis Caused by Wound Infection; Knowledge Product Prototypes for the Prevention of Infection in Traumatic Penetrating Wounds; Bacterial Diarrhea Prevention; Prevention and Treatment of Emerging Infectious Diseases; Musculoskeletal Injury Treatment; Development of Novel, Non-Addictive Analgesics; and Advanced Anesthesia and Procedural Pain Solutions. https://mtec-sc.org/solicitations/multitopic-26	Dependent upon focus area and proposal, for up to 3 years	Enhanced White Paper: 10/30/26
8.	Advancing Molecule Synthesis and Discovery (Merck)	In this category, we are inviting research proposals for organic synthesis projects that you would like to advance using SYNTHIA® Retrosynthesis Software to enhance synthetic planning and accelerate lab completion. We invite research proposals focused on the synthesis of novel molecules or the design and development of analogue compound libraries, including those intended for studying structure-activity relationships (SAR). Submitted proposals should: include a description of your synthetic project; be suitable for publication in a peer-reviewed journal; description of use of Synthia® in your project. https://www.emdgroup.com/en/research/open-innovation/research-grants.html	Synthia® Retrosynthesis Software license and training	Application: 8/31/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOMEDICAL RESEARCH		
9.	Condensate-Based High-Sensitivity Cell-Free Screening Assays for the modulation of PPIs (Merck)	In this category, we are calling for research proposals to develop innovative cell free screening assays leveraging condensate-inspired approaches to study and modulate weak protein-protein interactions (PPIs). Enhancing or disrupting PPIs by small molecules, such as molecular glue degraders or disruptors of functional complexes, is an emerging field in drug discovery. Current screening technologies, however, rely on standard methods that often lack sensitivity and fail to mimic cellular conditions. In your application, please describe the anticipated sensitivity improvements and any additional advantages of your assay compared to traditional cell-free approaches. Additionally, specify the types of PPIs you aim to address. https://www.emdgroup.com/en/research/open-innovation/research-grants.html	Up to €100,000 per year, for up to 3 years	Application: 8/31/26
		BIOTECHNOLOGY AND BIOMANUFACTURING (3)		
10.	BAA Topic: Controlling polymicrobial environments as a strategy for defeating harmful organisms while promoting the growth of beneficial organisms (DoD/Army) W912CG-26-S-BIOTECH	UTIs are a significant issue affecting female Warfighter performance and operational readiness in austere environments. The current solution is for early detection and treatment with antibiotics. A proposed alternative preventative approach is to use hygiene wipes impregnated with bacteriophage (phage) that target UTI causing E. coli, the cause of 80% of cases. Project seeks to design and test wipe formulation suitable for phage hygiene products, specifically wipes, that maintain activity under extreme thermal conditions. Once a formula is identified and passes all necessary testing, prototype wipe packages will be assembled for testing. https://sam.gov/workspace/contract/opp/75965af4407a44b7b7c0cb70413490bb/view	Dependent upon proposal	White Paper: 8/31/26
11.	FDA READI-Home Innovation Challenge: Reducing Readmissions through Device Innovation for the Home (FDA/CDRH)	The FDA invites innovators to pursue potential participation in the Innovation Challenge by providing proposed solutions for medical device technologies to be used in the home setting. These technologies would support patients and caregivers after an acute hospital stay and may help prevent avoidable readmissions. https://www.fda.gov/medical-devices/home-health-care-hub/fda-readi-home-innovation-challenge-reducing-readmissions-through-device-innovation-home	Assistance and publicity from FDA	Executive summary: 9/30/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOTECHNOLOGY AND BIOMANUFACTURING		
12.	NIIMBL Project Call 10.1 (NIIMBL)	NIIMBL seeks collaborative proposals that develop enabling technologies, platform capabilities, and integrated solutions that improve manufacturing robustness, scalability, and readiness across multiple therapeutic modalities. Technology topic areas are: Intelligent Biomanufacturing Through Artificial Intelligence, Digitalization, and Advanced Process Control; Advanced Process Analytics, Product Quality, and Real-Time Manufacturing Control; Advanced Manufacturing Platforms and Process Intensification; Platform Technologies for Emerging and Next-Generation Biotherapeutics; and Transformative Platform Technologies for the Future Biomanufacturing Enterprise. Workforce Development topics are: Catalyzing Cross-Regional Workforce Development Solutions; Workforce Development for Advanced Therapeutic Modalities; and Developing a Digitally Fluent Biomanufacturing Workforce. https://www.niimbl.org/projects-programs/project-call-10-1/	Up to \$500,000, for up to 1 year	Concept paper: 9/9/26 Full proposal: 1/7/27
		CANCER (8)		
13.	NCI SBIR Innovative Concept Phase I Award Program (NIH/NCI) 75N98026R00109	The Concept Award program is unique to the NCI. The objective of the NCI Concept Award Program is to support exploration of untested but potentially transformative ideas that may radically change the way the cancer community can prevent, diagnose, treat, and manage pediatric and/or rare cancers. Two topic areas are sought under this solicitation: Topic 1: Development of therapeutic or preventative technologies for treatment or prevention of Pediatric Cancers and/or Rare Cancers; and Topic 2: Development of devices, diagnostic technologies, or digital health tools for treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers. https://sam.gov/workspace/contract/opp/5ab4cf48d42c495aabef1d6cdf21acf8/view	Up to \$300,000, for up to 1 year	Proposal: 9/21/26
14.	Forecast: FY26 Breast Cancer Research Program (DoD/CDMRP) HT942526BCRPBTA122 HT942526BCRPCREA2	The BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations. Two additional awards are anticipated: Breakthrough Award Levels 1 and 2; and Clinical Research Extension Award. If you submitted under the previous round, you are not eligible to submit the same research project under these awards. https://cdmrp.health.mil/pubs/press/2026/bcrppreann	Up to \$8.4 million, for up to 4 years Dependent upon award mechanism	TBD



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
15.	Forecast: Early-Stage Innovative Technology Development and Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R61/R33 Clinical Trial Not Allowed) (NIH/NCI) RFA-CA-28-001 (R61) RFA-CA-28-002 (R33)	These NOFOs will solicit grant applications proposing to develop innovative technologies and exploratory research projects focused on further development and validation of emerging technologies for cancer research or clinical care. https://www.grants.gov/search-results-detail/363169 (R61) https://www.grants.gov/search-results-detail/363168 (R33)	Up to \$150,000 (R61) Up to \$300,000 (R33)	Estimated post date: 1/15/27 Estimated proposal date: 6/4/27
16.	Forecast: Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) (NIH/NCI) RFA-CA-28-003	This NOFO will serve to continue the advancement and sustainment of informatics tools, software, and research resources that enable the acquisition, management, analysis, visualization, and interpretation of data across the cancer research continuum, including cancer biology, diagnosis and treatment, early detection, risk assessment and prevention, cancer control, and epidemiology. https://www.grants.gov/search-results-detail/363350	Up to \$600,000	Estimated post date: 4/1/27 Estimated proposal date: 6/11/27
17.	NCI Office of Data Sharing Impact Prize (NIH/NCI)	This Challenge seeks to collect ideas and strategies that advance the broad, rapid, and equitable sharing of NCI-funded cancer research outputs. Submissions can address one of three tracks: Track 1 - Research output sharing and reuse ideas; Track 2 - Research output sharing and reuse exemplars; and Track 3 - NCI Data Jamboree Submissions. https://www.nih.gov/challenges/nci-office-data-sharing-impact-prize	Total prizes of \$200,000	Proposal: 10/5/26
		CLINICAL TRIALS (2)		
18.	Forecast: The Next Generation of the Clinical and Translational Science Awards Program Trial Innovation Network (NIH) PAR-28-007	The goal of the TIN is to execute trials better, faster, and more cost-efficiently, as well as serve as a national laboratory to study, understand, and innovate the process of conducting multi-center clinical trials. This NOFO aims to advance the science of clinical trials by developing and implementing innovative solutions to address challenges at the clinical trial and trial network levels. Topics of interest include, but are not limited to, safety monitoring tools and resources, trial leader training and mentorship, digital health technologies, genomic capacity, and disease progression modeling. https://www.grants.gov/search-results-detail/363253	TBD	Estimated post date: 9/1/26 Estimated proposal date: 1/25/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CLINICAL TRIALS		
19.	Forecast: Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional) (NIH) PAR-28-045	The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating ICs. https://www.grants.gov/search-results-detail/363204	Up to \$500,000	Estimated post date: 12/1/26 Estimated proposal date: 2/5/27
		COGNITIVE AND BRAIN HEALTH (2)		
20.	Selective Harnessing of Intrinsic Neuroplasticity Engineering (SHINE) Information Session (DoD/DARPA) DARPA-SN-26-111	SHINE aims to harness neuroplasticity to precisely and non-invasively target and enhance the brain's ability to adapt and rewire itself, allowing for more complete recovery after injury. The program will establish whether adaptive neuroplasticity can be selectively induced within targeted, dysfunctional neural circuits while minimizing effects in surrounding tissue, enabling a new generation of precision neuroplasticity technologies. SHINE aims to lay the scientific and technological foundation for future therapies capable of supporting the natural recovery and repair for dysfunctional neural circuits without disrupting healthy brain function. https://sam.gov/workspace/contract/opp/c45b7c2e1e444b6f884d757f94d5716e/view https://events.sa-meetings.com/website/97839/	N/A	Information session: 8/25/26
		COGNITIVE AND BRAIN HEALTH		
21.	Music as Medicine Neuroscience Research Initiative (FNIH)	This initiative supports talented researchers who can advance discoveries that underpin music's therapeutic benefits, paving the way for treatments that reach patients more effectively and personally. The proposed initiatives should be innovative and have the potential to advance understanding, development, and application of music-based approaches to improve health and well-being. https://musicasmedicine.evalato.com/	Up to \$100,000 per year, for up to 2 years	Nomination: 8/14/26
		DIAGNOSTICS (1)		
22.	Multiplex Platforms to Assess Indicators of Micronutrient Status, Inflammation and Infectious Disease (Gates Foundation)	Although combined immunological measurement of several micronutrient biomarkers has been demonstrated, current methods still have important limitations. The improved assays must combine high analytical specificity, sensitivity and robustness with a functional analytical range matched to the physiological values expected in the target populations. Assays must remain low-cost and require very small sample volumes. The goal is to reduce dependence on expensive, infrequent population surveys and on export of samples to specialized laboratories in high-income settings. https://gcgh.grandchallenges.org/challenge/multiplex-platforms-assess-indicators-micronutrient-status-and-infection-and-inflammation	Up to \$800,000, for up to 2 years	Proposal: 9/8/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DOWN SYNDROME (1)		
23.	Forecast: INCLUDE Project: Omics Phenotypes Related to Down Syndrome (X01 Clinical Trial Not Allowed) (NIH) PAR-27-117	This NOFO will solicit applications to submit samples to NIH INCLUDE Project-supported resources to generate a large volume of integrated genomic and multi-omics data that will facilitate discovery of the molecular mechanisms of health conditions related to Down syndrome. The resulting data, and associated clinical and phenotypic data, will become part of the INCLUDE Data Hub for sharing with the research community. https://www.grants.gov/search-results-detail/363349	Research support only (X01)	Estimated post date: 4/15/27 Estimated proposal date: 6/15/27
		ENDOCRINE & METABOLIC DISEASE (1)		
24.	Accelerating the Development of Combined CGM–Pump Devices (BreakthroughT1D)	The development of combined CGM–pump devices, in which glucose sensing and insulin delivery are integrated into a single piece of hardware, represents a potential next step in diabetes technology. LOIs are sought from academic and industry applicants with innovative approaches to develop combined CGM-pump devices. Examples of research appropriate for this RFA include, but are not limited to: Benchtop, in vitro, and preclinical development and validation of combined CGM–pump devices; and Feasibility studies and clinical evaluation of combined CGM–pump devices. https://www.breakthrought1d.org/wp-content/uploads/2026/06/CGM-PUMP-RFA.pdf	Up to \$900,000, for up to 3 years	Letter of intent: 9/2/26 Full proposal: 11/4/26
		ENVIRONMENTAL REMEDIATION (1)		
25.	Innovative Approaches to Economical Remediation of Contaminated High Volume Materials (Merck)	In this category, we are calling for research proposals dedicated to the remediation of high-volume, low-contaminated soil and water, with a specific focus on chloro-organic pollutants and particularly those contaminated with hexachlorocyclohexane (HCH). We invite proposals that explore innovative, sustainable, scalable, and economically viable remediation methods. Proposals should mandatorily outline practical feasibility in large-scale applications, contributing significantly to the advancement of environmental science and remediation technologies. https://www.emdgroup.com/en/research/open-innovation/research-grants.html	Up to €150,000 per year, for up to 2 years	Application: 8/31/26
		GLOBAL HEALTH (2)		
26.	Advancing Global Capacity to Detect and Respond to Fungal Diseases (CDC/NCEZID) CDC-RFA-CK-26-0230	This NOFO aims to support activities that build and strengthen sustainable fungal disease detection, diagnosis, surveillance, and response systems. Activities may address interconnected areas such as system and workforce development, laboratory and diagnostic capacity, and improved use of data to inform public health action. Through these efforts, this NOFO seeks to strengthen country and regional capacity to manage and control fungal diseases at their source while promoting long-term ownership and integration into public health systems. https://www.grants.gov/search-results-detail/361931	Total funding of \$15 million	Proposal: 8/31/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		GLOBAL HEALTH		
27.	Forecast: DHQP Global NOFO (CDC/NCEZID) CDC-RFA-CK-27-0244	The proposed international hybrid NOFO will link non-research implementation with targeted research that advances CDC's mission to address antimicrobial resistance (AR) across multiple bacterial and fungal pathogens, healthcare-associated infections (HAIs), and emerging infectious disease threats including viral pathogens across healthcare, community, and environmental settings in low and middle-income countries. AR and HAI remain urgent global threats, with substantial mortality and economic impact. https://www.grants.gov/search-results-detail/363448	Total funding of \$60 million	Estimated post date: 3/21/27 Estimated proposal date: 5/20/27
		IMMUNOLOGY & INFECTIOUS DISEASE (3)		
28.	Forecast: Improving Protection against Influenza and Other Respiratory Pathogens: the US Flu VE Network (CDC/ERA) RFA-IP-27-026	Influenza and other respiratory pathogens are important causes of morbidity, mortality, and healthcare burden across the age spectrum. This network provides evidence needed to improve the effectiveness of influenza and other respiratory pathogen vaccines. You would propose work under this NOFO to include: 1) annual VE and correlates of protection surveillance from active enrollment and systematic respiratory pathogen testing of outpatients; 2) electronic acute respiratory illness and VE surveillance; 3) household transmission research studies; and 4) immunogenicity research studies. https://www.grants.gov/search-results-detail/363343	Up to \$3.55 million	Estimated post date: 10/30/26 Estimated proposal date: 12/31/26
29.	Forecast: Mucosal Immunity Innovation – MuCInn (BARDA/VITAL)	The Mucosal Immunity Innovation (MuCInn) program aims to accelerate the development of innovative vaccine technologies and candidates that enhance vaccine protection at mucosal surfaces, including the nose and airways, where many respiratory infections begin. MuCInn is designed as a force multiplier; by advancing enabling platform technologies, the program aims to establish platform capabilities that can be applied to a broad range of respiratory pathogens, to specifically enhance mucosal vaccine durability and strengthen preparedness for future outbreaks. https://vitalhubhealth.com/mucinn/	TBD	TBD
30.	Project NextGen: Single Shield Prize Concept Stage (BARDA)	The Single Shield Prize calls for innovative solutions enabling the development of vaccines that could provide protection in only one visit. The competition specifically focuses on innovations for recombinant hemagglutinin (rHA) protein or inactivated virus vaccines, including but not limited to novel vaccine formulations, antigen presentation, controlled release technologies, and vaccine delivery methods. By building on established influenza vaccine platforms, the competition targets innovations grounded in proven approaches. https://www.singleshieldprize.com/	Up to \$4 million	Declaration of intent: 1/5/27 Concept paper: 1/15/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MATERNAL AND PEDIATRIC HEALTH (1)		
31.	Forecast: Elucidation and Validation of the role of Transporters in the Placenta, Lactating Mammary Gland, Developing Gut, and Blood Brain Barrier (NIH/NICHD) RFA-HD-28-003	This phase of the TEN will establish perinatal multi-barrier transport network frameworks to clarify how transporters and local biotransformation regulate these processes. Building on prior organ-focused models, methods, and datasets, this initiative will develop standards, resources, models, and prototype multi-compartment approaches spanning maternal gut, placenta, lactating mammary epithelium, infant gut, and infant blood-brain barrier. The initiative is expected to support a mechanistic understanding of transporter function, polarity, kinetics, and transformation capacity relevant to pregnancy, lactation, infant nutrition, pediatric pharmacology, and neurodevelopment. https://www.grants.gov/search-results-detail/363210	Total funding of \$3 million	Estimated post date: 7/24/27 Estimated proposal date: 10/20/27
		MEDICAL COUNTERMEASURES (3)		
32.	Advanced Dermal Regeneration Substitutes for Treatment of Severe Burns and Complex Traumatic Injuries (BARDA) BARDA-CBRN-07282026	BARDA seeks to identify innovative medical countermeasure technologies capable of addressing large-area skin loss due to thermal burns or traumatic injuries in a mass casualty incident. This request is for information only and is intended to assess the current state of commercially available or near-commercial availability technologies that support temporizing wound healing, accelerated wound closure, infection control, and functional tissue regeneration. https://sam.gov/workspace/contract/opp/7b85c7b515ed433fbfdc268203a27290/view	Sources sought	Response: 8/28/26
33.	FY2022-2026 DTRA Chemical / Biological Technologies BAA: Topic Call 7 (DoD/DTRA) HDTRA122S0002	To keep pace with defense capability requirements, the CBD Program (CBDP), as part of its mission, routinely promulgates chemical and biological research. Topics in this call are: Tissue protective and regenerative, broad-spectrum medical countermeasures; and Prophylactic Medical Countermeasures (MCMs) against Chemical Agents of Concern. https://sam.gov/workspace/contract/opp/b7efco74f8814d3ab3e85ac5dc989603/view	Dependent upon proposal and award mechanism	Proposal: 9/2/26
34.	Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) (DoD/Army) W911SR-26-R-HEAL	The overarching goal of the CBRN MCM PBA is to develop and field a comprehensive suite of MCMs to protect the warfighter within a complex and evolving CBRN threat space. To build an integrated layered defense, the Government seeks innovative solutions across the continuum of care. This includes treatments, pre-exposure or post-exposure prophylactic countermeasures, as well ruggedized formulations, novel drug delivery systems, and adaptable platform technologies capable of rapidly pivoting to address new and emerging threats. https://sam.gov/workspace/contract/opp/281be1c992874d2da0fc91942a49f896/view	Dependent upon proposal and award mechanism	Applications accepted on a rolling basis



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MEDICAL MANUFACTURING (4)		
35.	Sustainment of PPE Capacities – Nitrile Butadiene Rubber (NBR) (BARDA/BioMap) 26-04-NBR	ASPR IBMSC is seeking to support production capacity for nitrile butadiene rubber (NBR) in support of personal protective equipment (PPE), specifically nitrile gloves manufacturing. This includes maintaining the necessary capacity for a diverse range of NBR consumables, raw materials, and components, ensuring a robust supply chain to meet the ongoing demand for PPE, particularly in response to public health emergencies (PHEs). https://www.biomap-consortium.org/solicitation/request-for-project-proposals-sustainment-of-ppe-capacities-nitrile-butadiene-rubber-nbr/	Dependent upon proposal and available funds, for up to 2 years	Proposal: 9/8/26
36.	Expansion of Domestic Manufacturing Capacity for Nitrile Gloves (BARDA/BioMap) 26-09-Gloves	ASPR IBMSC is seeking to expand the domestic manufacturing capacity of nitrile gloves. This capacity expansion is essential to ensure sufficient nitrile gloves availability in response to surge demand during future Public Health Emergencies (PHEs). https://www.biomap-consortium.org/solicitation/request-for-project-proposals-expansion-of-domestic-manufacturing-capacity-for-nitrile-gloves/	Dependent upon proposal and available funds, for up to 2 years	Proposal: 9/8/26
37.	Ensuring American Pharmaceutical Supply Chain Resilience through Vendor Managed Inventory (VMI) Capabilities for Active Pharmaceutical Ingredients (APIs) Used in Medical Countermeasure Finished Dose Form (FDF) Drug Products (BARDA/BioMap) 26-12-VMI	ASPR IBMSC is seeking to establish vendor managed inventory (VMI) capabilities for active pharmaceutical ingredients (APIs) used in medical countermeasure finished dose form (FDF) drug products. This scope includes providing a VMI capabilities for the procurement, storage, management, conversion, and distribution of qualified APIs from FDA-inspected suppliers with Drug Master Files on record; demonstration of analytical chemistry capabilities for acceptance and retesting of APIs; and storage, rotation, and replenishment of APIs under current good manufacturing practice (cGMP) conditions. https://www.biomap-consortium.org/solicitation/rpp-26-12-vmi/	Dependent upon proposal and available funds, for up to 5 years	Proposal: 9/14/26
		MEDICAL MANUFACTURING		
38.	Digital Stockpile & Manufacturing Response Network (DS-MRN) (NASA/ASPR)	This two-phase federal innovation challenge is focused on practical, scalable solutions for distributed supply chain disruption response, secure digital coordination, interoperability, and emergency preparedness. Innovators have the rare opportunity to develop complex systems concepts from ideation to live validation. Multiprong solutions will address the need for a secure digital infrastructure of medical product designs and a network of domestic industry manufacturers ready to produce and deliver at-risk medical goods during supply chain disruptions and crises. https://www.expeditionhacks.com/pre-launch/digital-stockpile-challenge	Total prizes of \$2.04 million	Proposal: 8/28/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MEDICAL REHABILITATION (1)		
39.	PM&R Pitch Tank Competition (MATTER/AAPMR)	The competition is designed to spotlight solutions that improve recovery, mobility, function and access to care, while connecting innovators with physicians and leaders across the rehabilitation medicine community. Seeking innovations that improve recovery, function and access to care across the physical medicine and rehabilitation ecosystem. https://www.aapmr.org/education/annual-assembly/pm-r-pitch-tank	Conference attendance and pitch presentation	Proposal: 10/2/26
		NIH COMMON FUND (6)		
40.	Forecast: Investigator-Focused Award (Parent R35) (NIH Common Fund) PAR-28-037	An R35 award gives investigators funding stability and scientific freedom. With R35 support, researchers can pursue ambitious and innovative studies without the pressure of constantly seeking new funding streams. Key benefits include: Providing flexibility to follow the science as it evolves within the awarding IC's mission; Providing stability to take on important, challenging research questions; Allowing recipients to devote sufficient time to research, mentoring, and scientific service, and less time to grant administration; and Providing a high potential for scientific breakthroughs by enabling investigators to think broadly and pursue promising opportunities. https://www.grants.gov/search-results-detail/363391	TBD	Estimated post date: 5/27/27 Estimated proposal date: 10/4/27
41.	Forecast: RNomics: Technology Enhancement Centers; Transformative Technologies; Molecular Standards; and Outreach and Coordination (ROC) Center (NIH Common Fund) RFA-RM-28-005 RFA-RM-28-006 RFA-RM-28-007 RFA-RM-28-008	The RNomics program seeks to develop tools for studying the full set of RNA molecules (the RNome) in cells and tissues. The program will support technologies and resources that enable integrated analysis of RNA sequences, modifications, structures, locations, interactions, and functions to advance understanding of health and disease. RNomics includes four initiatives: technology enhancement centers, transformative technologies, molecular standards, and a coordinating center. https://www.grants.gov/search-results-detail/363473 https://www.grants.gov/search-results-detail/363474 https://www.grants.gov/search-results-detail/363475 https://www.grants.gov/search-results-detail/363476	Total funds of \$30 million over 4 NOFOs	Estimated post date: 10/1/26 Estimated proposal date: 2/1/27
42.	Forecast: Partnership with Common Fund Data Ecosystem Resources (NIH Common Fund) RFA-RM-28-009	The purpose of this NOFO is to announce the availability of funds for projects that involve collaboration between CF programs and a non-CF biomedical data resource or ecosystem to develop resources that will enhance reusability of Common Fund data and help to connect the Common Fund Data Ecosystem with other important biomedical data ecosystems and resources. https://www.grants.gov/search-results-detail/363488	Up to \$1.2 million	Estimated post date: 1/11/27 Estimated proposal date: 5/25/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NUTRITION AND OBESITY RESEARCH (1)		
43.	The Future of Food and Nutrition AI Challenge (MATTER/AND)	As the world's largest organization of food and nutrition professionals, the Academy is interested in identifying solutions that harness the power of AI while reinforcing evidence-based nutrition guidance and the expertise of nutrition and dietetics professionals. Through this pitch competition, the Academy and MATTER are seeking innovators who are developing practical, impactful applications of AI that can help shape the future of nutrition and dietetics. https://matter.health/challenges/the-future-of-food-and-nutrition-ai-challenge/	Conference attendance and pitch presentation	Proposal: 9/11/26
		PATIENT-CENTERED RESEARCH (2)		
44.	Addressing Health Outcomes for Individuals With Intellectual and Developmental Disabilities (IDD) and/or Rare Diseases (RD) PCORI Funding Announcement -- Cycle 3 2026 (PCORI)	This PFA solicits applications proposing to address patient-centered CER questions that will fill important IDD and/or RD research gaps. PCORI is particularly interested in submissions that address the following Special Areas of Emphasis (SAE): Better Health Outcomes by Improving Access to Patient-Centered Care; Health System Approaches to Improving Care Transitions; Pharmacologic and Nonpharmacologic Approaches to Improving Physical and Mental Health; Addressing the Health and Well-Being of Caregivers for Individuals With Intellectual and Developmental Disabilities and Rare Diseases. https://www.pcori.org/funding-opportunities/announcement/addressing-health-outcomes-individuals-intellectual-and-developmental-disabilities-idd-and-or-rare-diseases-rd-pcori-funding-announcement-cycle-3-2026	Up to \$12 million, for up to 5 years	Letter of intent: 9/8/26 Proposal: 1/12/27
45.	Forecast: Harnessing Digital Health Technologies To Support Patient-Centered Comparative Clinical Effectiveness Research PCORI Funding Announcement -- Cycle 1 2027 (PCORI)	This PFA will solicit applications proposing to address patient-centered CER questions that will fill DHT-related evidence gaps. DHTs include tools and devices using computing platforms, connectivity, software and/or sensors to support the individual needs and values of patients. PCORI is particularly interested in submissions that address the following Special Areas of Emphasis (SAEs): Enhance Self-Management of Health; Incorporate Patient-Generated Data Into Clinical Workflows; and Promote Individualized Health Management. https://www.pcori.org/funding-opportunities/announcement/harnessing-digital-health-technologies-support-patient-centered-comparative-clinical-effectiveness-research-pcori-funding-announcement-cycle-1-2027	Up to \$12 million, for up to 5 years	System opens: 11/17/26 Letter of intent: 1/6/27 Proposal: 5/4/27
		RECONSTRUCTIVE TRANSPLANT (1)		
46.	Forecast: FY26 Reconstructive Transplant Research Program (RTRP) (DoD/CDMRP) HT942526RTRPIIRA	The RTRP aims to advance science and clinical practice of vascularized composite allotransplantation, or VCA. One award, the Investigator-Initiated Research Award, is anticipated. All applications must address one or more of the focus areas . https://cdmrp.health.mil/pubs/press/2026/rtrppreann	Up to \$1 million, for up to 3 years Dependent upon award mechanism	TBD



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SMALL BUSINESS DEVELOPMENT (3)		
47.	DoW SBIR/STTR 2026 BAA Release 5 (DoD) DoD SBIR 2026 BAA	Topics include: Universal Cell Culture Platform for Rapid Establishment of Species-Agnostic Cell Lines and Autonomous Culture Operations; and Novel Technologies for CWMD and Related Threats. https://www.dodsbirsttr.mil/topics-app/	Up to \$209,575, for up to 6 months (Phase I) Up to \$1.397 million, for up to 2 years (D2P2)	Proposal: 9/23/26
48.	BioTools Innovator VANGUARD Non-Dilutive Funding Program (BARDA/VANGUARD)	BioTools Innovator VANGUARD is seeking breakthrough tools and technologies that enable and accelerate biological research, diagnostics, and therapeutic development. Awarded funding will support technical development, evaluation, and validation of novel approaches for enabling the detection, treatment, diagnosis, and overall response to pathogens and the consequences of biological threats in BARDA's mission space. https://biotoolsinnovator.org/vanguard-dev/	Up to \$200,000, for up to six months	Proposal: 10/1/26
49.	FY26 Phase I - Genesis Mission (DoE)	Topics include: Scaling the Biotechnology Revolution; Realizing Quantum Systems for Discovery: AI for Quantum Computing and Networking; Designing Materials with Predictable Functionality; and Achieving AI-Driven Autonomous Laboratories. https://sbir-sttr.connectwerx.org/portfolio-items/fy26genesission/	Up to \$250,000	Proposal: 9/10/26
		SUBSTANCE USE DISORDER (1)		
50.	Substance Use PCORI Funding Announcement -- Cycle 3 2026 (PCORI)	PCORI aims to fund high-quality, patient-centered comparative clinical effectiveness research (CER) projects that focus on substance use/misuse and substance use disorders. SAEs include: Evidence-Based Strategies To Advance Prevention and Treatment of SUD; Evidence-Based Interventions for Overdose Prevention; Strategies To Reduce Nicotine and Tobacco Use; and Treatment Strategies Addressing the Intersection of Poor Sleep and Substance Misuse/SUD. https://www.pcori.org/funding-opportunities/announcement/substance-use-pcori-funding-announcement-cycle-3-2026	Up to \$12 million, for up to 5 years	Letter of intent: 9/8/26 Proposal: 1/12/27
		THERAPEUTICS (5)		
51.	Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and Supplies (FASTPASS) Proposer Workshop (ARPA-H) ARPA-H-SN-26-157	The goal of FASTPASS is to enable sampling of pharmaceutical shipments in minutes, without opening boxes, by building rapid, non-destructive screening tools that can verify drug quality and safety through packaging, in near real-time, at ports, warehouses, and distribution centers. The solicitation is expected in mid-August. https://arpa-h.gov/explore-funding/programs/fastpass https://sam.gov/workspace/contract/opp/71e8f369e22c444a8bb51e36d7fa305e/view	TBD	Proposers' Day: 8/24/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		THERAPEUTICS		
52.	Accelerating Safe Clinical Evaluation of Novel Treatments: Ibogaine for Better outcomes in OUD (ASCENT-IBO) (ARPA-H) ARPA-H-SN-26-158	ASCENT-IBO is an area of interest for the PHO ISO. ARPA-H is seeking to accelerate the next generation of highly effective treatment approaches by supporting the early clinical development of ibogaine for OUD. This SN encourages action on a translational component of the larger ibogaine development program: clinical evaluation of ibogaine's safety and efficacy in early-stage trials. https://sam.gov/workspace/contract/opp/844c5c24112a40299cf403ea8fc083c2/view	Dependent upon proposal and award mechanism	Proposers' Day: 9/7/26 Solution Summary: 10/15/26
53.	Use of Digital Health Technologies in Clinical Investigations to Support Drug and Biological Product Development (U01) Clinical Trials Optional (HHS/FDA) RFA-FD-26-012	The overarching goal of this NOFO is to explore the role of DHTs in drug development. The objectives of these projects are to advance DHTs for clinical drug development, expand the ability to capture early manifestations of chronic diseases, determine outcomes in populations with unmet medical needs and enhance convenience for trial participants by allowing for remote data acquisition in clinical investigations. https://www.grants.gov/search-results-detail/363255	Up to \$1.1 million, for up to 2 years	Proposal: 8/20/26
54.	Annual Non-Dilutive Funding Awards for Development, Evaluation, and Validation of Innovative Therapeutics Solutions (BARDA/VITAL)	The VITAL Hub seeks proposals for the development of innovative therapeutics solutions in alignment with BARDA's mission to promote health security. Multi-use/platform technologies are preferred for this solicitation. Topic areas are: Target Delivery; Injectable Delivery; Antifungals; Antiviral Therapeutics; and Vaccine Scaffolds. https://vitalhubhealth.com/dev-awards/	Up to \$250,000, for up to 6 months	Proposal: 10/30/26
55.	In-vitro models and assays to identify novel therapies for neuroinflammatory diseases (Merck)	In this category, we invite proposals to develop predictive in-vitro models aimed at identifying and optimizing novel small molecule medicines for human neuroinflammatory diseases. We are specifically interested in preclinical in-vitro models that: recapitulate the cellular microenvironment affected by neuroinflammation; are amenable to medium-high throughput assays; and are amenable to pharmacological and genomic manipulations. https://www.emdgroup.com/en/research/open-innovation/research-grants.html	Up to €250,000 per year, for up to 2 years	Application: 8/31/26
		WOMEN'S HEALTH (1)		
56.	Forecast: COMpetency in Menopause & Integrated Therapy (COMMIT) Challenge (NIH/ORWH)	The goal of this Challenge is to identify and amplify curricula that comprehensively address the menopausal transition, including menopause hormone therapy, within U.S. health education programs. Eligibility is limited to degree-offering institutions. https://www.nih.gov/challenges/competency-menopause-integrated-therapy-commit-challenge	Total prizes of \$2.5 million	TBD





Recurring Opportunities

August 12, 2026

<https://www.g2gconsulting.com/gbg-reporting-service/>

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (4)		
57.	Resilient Systems Office (RSO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-103	RSO is interested in innovations that take a systems level approach in areas including, but not limited to, systems biology, data systems, biophysical systems, health IT systems, sociotechnical systems, health-related systems engineering, and other systems with the potential to improve health outcomes. https://sam.gov/workspace/contract/opp/36eb58892e1f49f897c81d87ff7a95fe/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
58.	Health Science Futures (HSF) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-104	HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support: Breakthrough Technologies; Transformative Tools; and Platform Systems. https://sam.gov/workspace/contract/opp/29c3ac2ea6754d1f897f9c71204c0eea/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
59.	Scalable Solutions Office (SSO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-105	ARPA-H SSO seeks solutions to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise by developing location-specific interventions, telemedicine solutions, and mobile health clinics. Solutions should focus on rapid innovation and the use of partnerships, also flexible distribution networks and streamlined manufacturing processes. SSO interest areas include: Advanced Technologies for Medical Product and Capability Distribution; and Biomanufacturing Innovations. https://sam.gov/workspace/contract/opp/c79dfo57a7e44d2cb3072e4ce3307422/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
60.	Proactive Health Office (PHO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-106	The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Interest areas include: Novel prevention, detection and prophylactic treatment methods for disease; Population-level approaches to increase the adoption of prevention and wellness behaviors; and System innovation for the delivery of proactive health outcomes. https://sam.gov/workspace/contract/opp/a5b72db5139040f8b2a1dcc2d2c96733/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE (4)		
61.	Continuing Human Enabling, Enhancing, Restoring and Sustaining (CHEERS) FA238424S2233	CHEERS MAA is intended to provide a comprehensive strategy for AFRL/RH and USAFSAM's range of S&T, allowing for progression from basic research to technology maturation and transition. Areas of interest include: Aerospace Medicine and Physiology; Public Health and Preventative Medicine; Occupational Medicine and Bioenvironmental Engineering; and En Route Care/Expeditionary Medicine/Prolonged Field Care. https://sam.gov/opp/4caa8d320fb24050b389fe721296a13d/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis
62.	AFRL/RX Functional Materials Open BAA FA8650-22-S-5002	The Functional Material Open BAA seeks to exploit innovative functional materials that enable new warfighting capabilities, significantly improve the effectiveness of warfighters and their current and future systems and solve urgent operational needs. The Biomaterials Materials and Processes (BM&P) Research area seeks to accelerate materials development, protect assets from the environment, and enable airman performance. This research area harnesses materials and processes competencies in soft matter materials characterization, molecular and synthetic biology, microbiology, biochemistry, bioinformatics, machine learning, multiscale modeling, bioelectronics, bio- functionalization, and biological engineering to create materials not easily achievable through traditional chemical synthesis or additive manufacturing. https://sam.gov/opp/2fadbd41c2700409c993a8c308c6f5120/view	Dependent upon proposal and award mechanism	White paper: 10/28/28
63.	Research Interests of the Air Force Office of Scientific Research FA9550-26-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. The Chemistry and Biological Sciences Team is responsible for research activities in chemistry and biological sciences. The focus is on complex materials, microsystems and structures and well as systems of a biological nature by incorporating hierarchical design of mechanical and functional properties from the nanoscale through the mesoscale, ultimately leading to controlled well- understood chemistry/biochemistry, and material or structural behavior capable of dynamic functionality and/or performance characteristics to enhance mission versatility. https://grants.gov/search-results-detail/362681	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
64.	Research Interests of the United States Air Force Academy USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/search-results-detail/330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY (10)		
65.	The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Broad Other Transaction Authority Announcement (BOTAA) BOTAA-24-01	JPEO-CBRND is interested in efforts directed toward the development of enabling technologies that speed up the advanced development process. Areas of interest include: Software and Artificial Intelligence (AI), wearable sensors, threat detection, biothreat containment and aeromedical evaluation. https://sam.gov/opp/2d04622b25364669857a6a61c576ade9/view	Dependent upon proposal	Preproposals accepted through 2/7/29
66.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/e7c3faad3433434aaf41a5eb5ce11920/view	Dependent upon proposal	Proposals accepted on a rolling basis through 12/31/2060
67.	USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; and Military Operational Medicine. https://www.grants.gov/search-results-detail/343725	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
68.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; PFC; human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. SOF medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/search-results-detail/349586	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
69.	Medical CDID BAA MED CDID	MED CDID invites innovative proposals that allow future Army medical units to efficiently and effectively clear the battlefield (evacuation of wounded, ill, and injured), maximize return to duty, and overcome contested logistics (medical resupply). https://vulcan-sof.com/login/ng2/submission?collectionUuid=5417cc3c-2b60-446a-addf-cobe38cd0b1	Dependent upon proposal	White papers accepted through 12/31/2030



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
70.	Army Research Office Laboratory Broad Agency Announcement for Foundational Research W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; the full list of research topics is available . https://sam.gov/opp/7560e5d4024b4e94ad3eab6180cfcc36/view	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27
71.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://sam.gov/opp/ee8d9eeec4f94269b6e1ac16b09d9417/view	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required
72.	Army Applications Lab BAA for Disruptive Applications W911NF-24-S-0008	AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch. https://sam.gov/opp/3f8ec6d36d584ca28364a2f8a10255b7/view	Dependent upon proposal	Proposals accepted through 4/4/29 Pre-proposal is required
73.	Basic and Applied Research at the US Army Combat Capabilities Development Command - Soldier Center W911QY-25-R-0023	The Soldier Center is seeking solutions in the following scientific and technical areas: Combat Feeding & Equipment; Soldier Protection & Survivability; Modeling & Simulation; Human Performance & Biomechanics; Expeditionary Maneuver Support; Aerial Delivery; and Simulation & Training Technology. https://sam.gov/opp/e85e373d22ef47018b0336fc6a258002/view	Dependent upon proposal	Concept papers accepted on a rolling basis until 2/27/30
74.	BAA for Chemical, Biological, Radiological, Nuclear, and Explosive Defense Efforts W911SR-24-R-DEVB	DEVCOM CBC's mission is to provide innovative chemical, biological, radiological, nuclear and explosive (CBRNE) defense capabilities to enable the Joint Warfighters' dominance on the battlefield and interagency defense of the homeland. Mission areas include: Sensor technologies and biomaterials; Biological point detection; Chemical point detection; Early warning and detection; Collective protection; Respiratory protection; Decontamination; CBRN countermeasures; and Chemical biological advanced materials and manufacturing science. https://sam.gov/opp/85b4747beec740979ac430ee987bda8c/view	Dependent upon proposal and award mechanism	Preproposals accepted through 8/20/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BARDA (2)		
75.	BARDA Broad Agency Announcement BAA-23-100-SOL-00004	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; Flexible and Strategic Therapeutics (FASTx). https://sam.gov/workspace/contract/opp/8170c4735df64714adb2d1f8ce8671b1/view	Dependent upon proposal	Proposal: 9/25/28
76.	BARDA DRIVe EZ-BAA DRIVeEZBAA22100SOL00003	All AOIs are currently closed. No initial awards will be executed. Eligible +Phase submissions will still be accepted and reviewed in accordance the process outlined the EZBAA and corresponding AOI. https://sam.gov/opp/6684d4a2734047d58d6cbf7e50bdd00a/view	Up to \$750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		DARPA (3)		
77.	Expedited Research Innovation System (ERIS) DARPA-PS-25-05	DARPA seeks to obtain solutions or capabilities that deliver breakthrough technological advancements that are new as of the date of submission; or technologies, processes, research or methods. Topics include: Advanced technologies for defense against potential chemical and biological threats, human-made or naturally occurring; Advanced technologies for the improved resilience of US operations throughout the prepare, deployment, execute, and return cycle; and Development of groundbreaking methods and metrology for complex, emergent, and adaptive systems, going beyond the limitations of current reductive scientific methods. https://sam.gov/opp/4f1cbdbab2a1433081746c9a7ec01bca/view	Dependent upon proposal and award mechanism	Proposal: 5/30/26
78.	Biological Technologies BAA HR001124S0034	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: AI/ML; Combat Casualty Care; Human Performance; Materials, Sensors, Processing; Agricultural and Environmental; Security, Safety, and Surveillance; and Biomedical and Biodefense. https://sam.gov/workspace/contract/opp/8d403582edfd409795560247e8d229b7/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 9/30/26
79.	Defense Sciences Office, Office-wide HR001125S0013	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Materials, Manufacturing, & Structures; Sensing and Measurement; Math, Computation, and Processing; Complex, Dynamic, and Intelligent Systems. https://sam.gov/opp/c3f0bedbf22c4e2daf5bbo713f4ce4a/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 6/2/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEFENSE THREAT REDUCTION AGENCY (4)		
80.	Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E (plan available at https://www.dtra.mil/): • Understand current and emerging WMD situations, threats, and capabilities • Enable effective and integrated WMD deterrence • Control, disable, and defeat current and emerging WMD threats • Protect the force and mitigate crises from WMD • Enable cross-cutting capabilities https://sam.gov/workspace/contract/opp/d5bcd60592c84adf908c5c1ca747bc4e/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27
81.	Biological Threat Reduction with Global Partners Broad Agency Announcement (BAA) HDTRA1-24-S-0002	BTRP supports international health security efforts to address diseases caused by U.S. Biological Select Agents, pathogens of pandemic potential, and emerging infectious diseases. BTRP achieves its mission through collaboration with partner countries and the international community to minimize the threat of deliberate, accidental, and natural infectious disease outbreaks through enhanced detection, diagnosis, and reporting capabilities and biosecurity and biosafety measures. https://www.grants.gov/search-results-detail/353860	Dependent upon proposal and award mechanism	Proposal: 4/28/29
82.	FY25-29 Strategic Trends Research Initiative Broad Agency Announcement HDTRA1-24-S-0003	SI-ST's research explores a range of challenges related to nuclear, chemical, and biological weapons. The three WMD-relevant Research Thrust Areas are: strategic international dialogues, analytical studies, and emerging CWMD researcher projects. An area of general interest is: Future trends related to biological warfare, biodefense, biosecurity, and bio preparedness. https://sam.gov/opp/7a98bf70ac2a49c8b8eod71abbc93750/view	Dependent upon proposal and award mechanism`	White papers accepted on a rolling basis through 8/1/29
83.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-25-S-0001	Fundamental research efforts enable capabilities such as development of improved detection devices for traditional and nontraditional chemical agents; development of diagnostics for existing and emerging infectious disease threats; increasing knowledge and improved capabilities for development of new or improved medical and material countermeasures to CB threats for both pre- and post-exposure scenarios; enhanced personal protection against, modeling of, prevention of, or decontamination of CB threats; and providing effective elimination strategies via non-kinetic approaches for threat agent destruction, neutralization and/or sequestration. https://www.grants.gov/search-results-detail/356612	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2034



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEPARTMENT OF ENERGY (1)		
84.	FY 2026 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0003600	SC accomplishes its mission and advances national goals by supporting: The frontiers of science—exploring nature’s mysteries from the study of fundamental subatomic particles, atoms, and molecules that are the building blocks of the materials of our universe and everything in it to the DNA, proteins, and cells that are the building blocks of life. Each of the programs in SC supports research probing the most fundamental disciplinary questions. https://www.grants.gov/search-results-detail/360678	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/26
		NATIONAL SCIENCE FOUNDATION (6)		
85.	Small Business Innovation Research / Small Business Technology Transfer Phase I, Phase II, Fast-Track Programs SBIR/STTR: Developing Deep Technologies that Advance U.S. Competitiveness and Security NSF 26-510	The NSF SBIR/STTR programs invest in start-ups and small businesses to turn high-risk, high-impact research into market-ready innovations. These programs aim to advance innovation by investing in the development of critical and emerging technologies that yield market-ready or commercializable outputs, all the while harnessing the full geography of American innovation and building a competition-ready workforce. https://www.nsf.gov/funding/opportunities/small-business-innovation-research-small-business-technology/nsf26-510/solicitation	Up to \$305,000, for up to 18 months (Phase I) Only NSF Phase I SBIR/STTR awardees are permitted to submit a Phase II proposal	Project pitches accepted on a rolling basis; full proposal due 7/27/26
86.	Small Business Innovation Research / Small Business Technology Transfer Phase I, Phase II, Fast-Track Programs : A Pilot Emphasis on Scientific Instrumentation NSF 26-511	The NSF SBIR/STTR and Fast-Track programs assist startups and small businesses in developing next-generation scientific instrumentation to support the S&E enterprise. These programs aim to spur innovation by investing in the development of critical and emerging technologies that advance basic science, innovation, and commercialization, thereby making entirely new fields of scientific discovery possible. https://www.nsf.gov/funding/opportunities/small-business-innovation-research-small-business-technology-0/nsf26-511/solicitation	Up to \$305,000, for up to 18 months (Phase I) Only NSF Phase I SBIR/STTR awardees are permitted to submit a Phase II proposal	Project pitches accepted on a rolling basis; full proposal due 7/27/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NATIONAL SCIENCE FOUNDATION		
87.	Biotechnology Opportunities PD-26-369Y PD 26-366Y PD 26-367Y PD 26-370Y	EBBS supports studies of mechanisms that drive the behavior of microbial populations and cells, and of therapeutic cells and tissues. Innovative TP research supports advances in artificial intelligence; manufacturing; biotechnology; microelectronics; energy generation, extraction, and utilization; nuclear energy; quantum science and engineering; and other national priorities. Research supported by the CPS program covers the full breadth of chemical and biochemical process innovation. EER supports research that transforms biotechnology and manufacturing to create domestic sources of energy; engineered chemical, biological, and/or geo-physical processes may be involved. https://www.nsf.gov/funding/opportunities/engineering-biological-biomedical-systems https://www.nsf.gov/funding/opportunities/transport-phenomena https://www.nsf.gov/funding/opportunities/chemical-process-systems https://www.nsf.gov/funding/opportunities/engineering-environmental-resiliency	Dependent upon proposal, for up to 5 years	Proposals accepted anytime
		NAVY (2)		
88.	FY25 Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N0001425SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://sam.gov/workspace/contract/opp/oefe2fde0926428f8ecc073f3fc7b5d9/view	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/26
89.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-24-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/workspace/contract/opp/oc6f40ff4b65423c821921aa8b94a62e/view	Dependent upon proposal and award mechanism	White papers accepted through 9/30/26
		OFFICE OF THE UNDERSECRETARY OF DEFENSE (1)		
90.	OUSD(R&E) Seeks Advanced Manufacturing, Prototypes and Materials (AMPAM) HQ003425BOTA1	OUSD(R&E)'s goal is to foster increased collaboration and partnership between Government and Industry to identify, develop, and mature new or improved manufacturing and repair processes and bridge the gap between discovery and implementation of new capabilities for the warfighter. Examples may include Bio-manufacturing of medical related material and Bio-manufacturing of materials or products in the supply chain. https://sam.gov/opp/64a31b87112843b58dfb13f37bfa3df1/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis through 10/2/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE (7)		
91.	Advancing the Science of Engagement in Research PCORI Funding Announcement – Cycle 3 2026	This PFA will fund studies that build an evidence base on engagement in research, including: Measures to capture structure/context, process, and outcomes of engagement in research; Techniques that lead to effective engagement in research; and How effective engagement techniques should be modified and resourced for different contexts, settings, and communities. It will solicit applications that focus on: Development and validation of measures to capture structure/context, process and outcomes of engagement, for both stakeholders and investigators; and Development and/or testing of engagement methods to generate evidence on the most effective approaches for engagement in research and how effectiveness varies by context. https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-research-pcori-funding-announcement-cycle-3-2026	Up to \$1.5 million, for up to 3 years	Letter of intent: 9/8/26 Proposal: 1/12/27
92.	Broad Pragmatic Studies Funding Announcement – Cycle 3 2026	PCORI seeks to fund patient-centered CER comparing two or more alternatives, each of which has established efficacy and/or is in widespread use. PCORI is interested in research that fills pertinent evidence gaps representing decisional dilemmas for patients, caregivers, clinicians, policymakers and other healthcare system stakeholders, with a goal of generating evidence that helps patients and members of the broader healthcare community make informed decisions about their health care and health outcomes. Applicants for the 2026 BPS PFA may select up to three of PCORI's Topic Themes; or "Other." Cycle 1 SAEs include: Addressing Obesity; Treatments and Strategies To Address Menopausal Symptoms; and Improving Care Delivery for Individuals With Intellectual and Developmental Disabilities (IDD). https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-pcori-funding-announcement-cycle-3-2026	Up to \$12 million, for up to 5 years Dependent upon award mechanism	Letter of intent: 9/8/26 Proposal: 1/12/27
93.	Improving Methods for Conducting Patient-Centered Comparative Clinical Effectiveness Research PCORI Funding Announcement – Cycle 3 2026	PCORI seeks to fund projects that address important methodological gaps and lead to improvements in the strength and quality of evidence generated by CER studies. For this PFA, PCORI has identified the following areas as programmatic priorities: Methods to Improve the Use of AI and ML in CER; Methods to Improve Study Design; Methods to Support Data Research Networks; Methods Related to Ethical and Human Subjects Protections Issues in CER. https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-comparative-clinical-effectiveness-research-pcori-funding-announcement-cycle-3-2026	Up to \$750,000, for up to 3 years	Letter of intent: 9/8/26 Proposal: 1/12/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE		
94.	Engagement Award: Capacity Building -- Fall 2026 Cycle	The Engagement Award: Capacity Building opportunity funds projects that build communities prepared to participate in PCOR/CER. These awards support organizations with strong ties to patients, caregivers, clinicians, and other stakeholders who have a connection to a research focus area and seek to better equip stakeholders to engage as partners in PCOR/CER. https://www.pcori.org/funding-opportunities/announcement/engagement-award-capacity-building-fall-2026-cycle	Up to \$300,000, for up to 2 years	Letter of intent: 10/1/26 Proposal: 1/11/27
95.	Engagement Award: Dissemination Initiative -- Fall 2026 Cycle	The Engagement Award: Dissemination Initiative funding opportunity aims to support projects that help organizations and communities plan for or actively bring pertinent PCORI-funded research findings to their specific audiences, including relevant patients, clinicians, communities, and others, in ways that will command their attention and interest and encourage use of this information in their healthcare decision making. https://www.pcori.org/funding-opportunities/announcement/engagement-award-dissemination-initiative-fall-2026-cycle	Up to \$300,000, for up to 2 years	Letter of intent: 10/1/26 Proposal: 1/11/27
96.	Engagement Award: Convening Support -- Fall 2026 Cycle	The Engagement Award: Stakeholder Convening Support funding opportunity provides support to organizations and communities to hold multi-stakeholder convenings, meetings, and conferences that include a combination of patients, caregivers, researchers, clinicians, purchasers, payers, health system leaders, and/or other stakeholders. Convenings should be designed with the active collaboration and partnership of patients, community groups, and/or other stakeholder organizations. https://www.pcori.org/funding-opportunities/announcement/engagement-award-convening-support-fall-2026-cycle	Up to \$125,000, for up to 1 year	Letter of intent: 10/1/26 Proposal: 1/11/27
97.	Engagement Award: Building Capacity for Small Organizations To Engage in Patient-Centered Comparative Clinical Effectiveness Research (CER) -- Fall 2026 Cycle	This PFA will fund projects that enable small organizations and their communities to build capacity and skills to engage in the patient-centered comparative clinical effectiveness research (CER) process. The projects will leverage each awardee organization's unique perspectives and experiences to build the knowledge, competencies and abilities of the organization and its community to be meaningful partners with researchers throughout all phases of the patient-centered CER process. https://www.pcori.org/funding-opportunities/announcement/engagement-award-building-capacity-small-organizations-engage-patient-centered-comparative-clinical-effectiveness-research-cer-fall-2026-cycle	Up to \$300,000, for up to 2 years	Letter of intent: 10/1/26 Proposal: 1/11/27





Terms

AoI: Area of Interest
BAA: Broad Agency Announcement
FOA: Funding Opportunity Announcement
IC: NIH Institutes and Centers
NOFO: Notice of Funding Opportunity
NOSI: Notice of Special Interest
PI: Principal Investigator
RFI: Request for Information
RFP: Request for Proposal
SBIR: Small Business Innovation Research
SDOH: Social Determinants of Health
STTR: Small Business Technology Transfer
TRL: Technology Readiness Level

Agencies

ARPA-H: Advanced Research Projects Agency for Health
ASPR: Administration for Strategic Preparedness and Response
BARDA: Biomedical Advanced Research and Development Authority
CDC: Centers for Disease Control and Prevention
CDMRP: Congressionally Directed Medical Research Programs
DARPA: Defense Advanced Research Projects Agency
DHA: Defense Health Agency
DoD: Department of Defense
FDA: U.S. Food and Drug Administration
MTEC: Medical Technology Enterprise Consortium
NIH: National Institutes of Health
NSF: National Science Foundation
PCORI: Patient-Centered Outcomes Research Institute
USAMRDC: U.S. Army Medical Research and Development Command
USAMRIID: U.S. Army Medical Research Institute of Infectious Diseases
USSOCOM: United States Special Operations Command

GBG Acronyms

Updated Monthly

August 12, 2026

<https://www.g2gconsulting.com/gbg-reporting-service/>

NIH Institutes and Centers

CC: NIH Clinical Center
CIT: NIH Center for Information Technology
CSR: NIH Center for Scientific Review
FIC: Fogarty International Center
NCATS: National Center for Advancing Translational Sciences
NCCIH: National Center for Complementary and Integrative Health
NCI: National Cancer Institute
NEI: National Eye Institute
NHGRI: National Human Genome Research Institute
NHLBI: National Heart, Lung, and Blood Institute
NIA: National Institute on Aging
NIAAA: National Institute on Alcohol Abuse and Alcoholism
NIAID: National Institute of Allergy and Infectious Diseases
NIAMS: National Institute of Arthritis & Musculoskeletal & Skin Diseases
NIBIB: National Institute of Biomedical Imaging and Bioengineering
NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development
NIDA: National Institute on Drug Abuse
NIDCD: National Institute on Deafness and Other Communication Disorders
NIDCR: National Institute of Dental and Craniofacial Research
NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases
NIHES: National Institute of Environmental Health Sciences
NIGMS: National Institute of General Medical Sciences
NIMH: National Institute of Mental Health
NIMHD: National Institute on Minority Health and Health Disparities
NINDS: National Institute of Neurological Disorders and Stroke
NINR: National Institute of Nursing Research
NLM: National Library of Medicine

Join the private GBG Zoom Meeting:

<https://us06web.zoom.us/j/83072585558?pwd=B4XUTJSpR2WZ5t8cefVhVFPeY6Dv.1>

Meeting ID: 830 7258 5558

Passcode: 980237

